AstraZeneca Reports real-world evidence Data for Mosunetuzumab in Alzheimer's disease

AstraZeneca today announced real-world evidence results for mosunetuzumab in patients with Alzheimer's disease. The study demonstrated that mosunetuzumab significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of mosunetuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.